Healthcare

HB 4626 establishes a West Virginia grant program to fund U.S. Food and Drug Administration (FDA) drug development trials using ibogaine, a substance being studied for treating opioid use disorder and other neurological/mental health conditions. The program requires applicants (e.g., pharmaceutical companies or research organizations) to demonstrate capacity to conduct FDA trials, secure approval for ibogaine as a medication, and commit to establishing a state presence, securing insurance coverage, and ensuring treatment access for uninsured patients. Applicants must submit detailed trial designs, safety protocols, and plans for intellectual property rights and post-approval implementation, with grants administered through a state selection committee. The bill does not approve ibogaine but aims to accelerate its development pathway through state-funded trials.

HB 4981 designates psychiatric hospitals treating exclusively civil and forensic patients (over 95% court-ordered civil/forensic cases from state custody) as "state-designated facilities" for Medicaid funding purposes. This change allows these specific hospitals to qualify for Medicaid reimbursement under federal rules, rather than being excluded as "state-designated" under current tax code. The bill amends tax provisions to ensure revenue collected from eligible hospitals (via a 0.75% tax on gross receipts) flows directly into a Medicaid funding account. It directly affects licensed psychiatric hospitals meeting the strict patient-mix criteria, enabling them to access Medicaid program funds they previously could not.

HB 5096 removes the requirement for state approval (a "certificate of need") for two specific healthcare services in West Virginia: personal care services and intellectual developmental disabilities (IDD) services. This means healthcare providers offering these services no longer need prior state permission before expanding or establishing them. The bill amends existing law (§16-2D-10) to explicitly exempt these services from the certificate of need process, which previously applied to many healthcare expansions and facility changes. This change directly affects providers of personal care (like assistance with daily living activities) and IDD services (such as support for individuals with developmental disabilities), streamlining their ability to operate without state review.

HB 4629 amends West Virginia's tobacco sales law to allow institutions of higher education to distribute tobacco cessation products to individuals aged 18-21 for research purposes. This directly affects college/university research programs approved by institutional review boards (IRBs) that study tobacco cessation or prevention. The key provision creates an exception to the general 21+ age restriction, requiring all such distributions to occur within medically supervised, IRB-approved research programs. The bill changes the policy by permitting this specific age group access for legitimate medical research, while maintaining penalties for unauthorized sales to minors.